Lung Cancer Clinical Trial

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Summary

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

View Full Description

Full Description

This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Male or female, at least ≥ 18 years.
NSCLC, of non-squamous histology.
Stage IA2 or IA3 disease, based on TNM8 classification.
Complete surgical resection (R0) of the primary NSCLC by lobectomy, segmentectomy or sleeve resection.
Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
World Health Organization performance status of 0 or 1.
Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.
Minimum life expectancy of > 6 months.
Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.

Exclusion Criteria

Mixed small cell and non-small cell cancer history.
Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy, bilobectomy or only wedge resection.
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and HIV.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.

Any of the following cardiac criteria:

Mean resting QTc interval > 470 ms, obtained from triplicate ECGs performed at screening.
Any abnormalities in rhythm, conduction, or morphology of resting ECG,
Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
History of interstitial lung disease.
Inadequate bone marrow reserve or organ function.
Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.
Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

380

Study ID:

NCT05120349

Recruitment Status:

Recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 163 Locations for this study

See Locations Near You

Research Site
Anchorage Alaska, 99508, United States
Research Site
Los Angeles California, 90024, United States
Research Site
Orange California, 92868, United States
Research Site
San Francisco California, 94143, United States
Research Site
Grand Junction Colorado, 81501, United States
Research Site
Atlanta Georgia, 30322, United States
Research Site
Chicago Illinois, 60612, United States
Research Site
Lexington Kentucky, 40508, United States
Research Site
Louisville Kentucky, 40217, United States
Research Site
Frederick Maryland, 21702, United States
Research Site
Morristown New Jersey, 07960, United States
Research Site
New York New York, 10029, United States
Research Site
White Plains New York, 10601, United States
Research Site
Greensboro North Carolina, 27403, United States
Research Site
Winston-Salem North Carolina, 27157, United States
Research Site
Houston Texas, 77030, United States
Research Site
Fort Belvoir Virginia, 22060, United States
Research Site
Seattle Washington, 98101, United States
Research Site
Buenos Aires , C1431, Argentina
Research Site
Caba , 1426, Argentina
Research Site
Caba , C1012, Argentina
Research Site
Cipolletti , 8234, Argentina
Research Site
La Plata , 1900, Argentina
Research Site
Rosario , S2000, Argentina
Research Site
Rosario , S2000, Argentina
Research Site
S.C. De Bariloche , 8400, Argentina
Research Site
Barretos , 14784, Brazil
Research Site
Blumenau , 89030, Brazil
Research Site
Ibirapuera , 04501, Brazil
Research Site
Porto Alegre , 90610, Brazil
Research Site
Recife , 52010, Brazil
Research Site
Rio de Janeiro , 22271, Brazil
Research Site
Sao Paulo , 01327, Brazil
Research Site
Vancouver British Columbia, V5Z 1, Canada
Research Site
Montreal Quebec, H2X 3, Canada
Research Site
Montreal Quebec, H4A 3, Canada
Research Site
Toronto , M5G 2, Canada
Research Site
Beijing , 10002, China
Research Site
Beijing , 10014, China
Research Site
Beijing , 10019, China
Research Site
Beijing , 10021, China
Research Site
Beijing , 10073, China
Research Site
Beijing , 10073, China
Research Site
Beijing , 10221, China
Research Site
Changchun , 13001, China
Research Site
Changchun , 13002, China
Research Site
Changsha , 41001, China
Research Site
Changsha , 43003, China
Research Site
Chengdu , 61000, China
Research Site
Fuzhou , 35001, China
Research Site
Guangzhou , 51006, China
Research Site
Guangzhou , 51010, China
Research Site
Guiyang , 55000, China
Research Site
Hangzhou , 31000, China
Research Site
Hangzhou , 31002, China
Research Site
Harbin , 15004, China
Research Site
Jinan , 25011, China
Research Site
Nanjing , 21002, China
Research Site
Shanghai , 20003, China
Research Site
Shanghai , 20003, China
Research Site
Shanghai , 20003, China
Research Site
Shanghai , 20043, China
Research Site
Shenyang , 11000, China
Research Site
Shenyang , 11004, China
Research Site
Shenzhen , 51811, China
Research Site
Suzhou , 21500, China
Research Site
Taiyuan , 03000, China
Research Site
Wuhan , 43006, China
Research Site
Xi'an , 71006, China
Research Site
Xintai , 54031, China
Research Site
Yangzhou , 22500, China
Research Site
Zhengzhou , 45000, China
Research Site
Berlin , 13125, Germany
Research Site
Esslingen , 73730, Germany
Research Site
Georgsmarienhuette , 49124, Germany
Research Site
Hannover , 30625, Germany
Research Site
Homburg , 66421, Germany
Research Site
Lübeck , 23538, Germany
Research Site
München , 81377, Germany
Research Site
Oldenburg , 26121, Germany
Research Site
Würzburg , 97067, Germany
Research Site
Bari , 70124, Italy
Research Site
Catania , 95100, Italy
Research Site
Firenze , 50134, Italy
Research Site
Genova , 16132, Italy
Research Site
Milan , 20141, Italy
Research Site
Napoli , 80131, Italy
Research Site
Padova , 35128, Italy
Research Site
Parma , 43100, Italy
Research Site
Roma , 00144, Italy
Research Site
Torino , 10122, Italy
Research Site
Chiba-shi , 260-0, Japan
Research Site
Fukuoka-shi , 812-8, Japan
Research Site
Hiroshima-shi , 734-8, Japan
Research Site
Kashiwa , 227-8, Japan
Research Site
Koto-ku , 135-8, Japan
Research Site
Kyoto-shi , 606-8, Japan
Research Site
Nagoya-shi , 464-8, Japan
Research Site
Niigata-shi , 951-8, Japan
Research Site
Osaka-shi , 541-8, Japan
Research Site
Osakasayama-shi , 589-8, Japan
Research Site
Sendai-shi , 980-0, Japan
Research Site
Shinjuku-ku , 160-0, Japan
Research Site
Sunto-gun , 411-8, Japan
Research Site
Wakayama-shi , 641-8, Japan
Research Site
Busan , 48108, Korea, Republic of
Research Site
Cheongju-si , 28644, Korea, Republic of
Research Site
Daegu , 42415, Korea, Republic of
Research Site
Gyeongsangnam-do , 52727, Korea, Republic of
Research Site
Seoul , 03080, Korea, Republic of
Research Site
Seoul , 07061, Korea, Republic of
Research Site
Seoul , 138-7, Korea, Republic of
Research Site
Suwon , 16247, Korea, Republic of
Research Site
Suwon , 16499, Korea, Republic of
Research Site
Kuala Lumpur , 59100, Malaysia
Research Site
Kuching , 93586, Malaysia
Research Site
Pulau Pinang , 10450, Malaysia
Research Site
Selangor , 46050, Malaysia
Research Site
Olsztyn , 10-35, Poland
Research Site
Poznań , 60-56, Poland
Research Site
Warszawa , 01-13, Poland
Research Site
Bucharest , 05009, Romania
Research Site
Galati , 6200, Romania
Research Site
Kazan , 42002, Russian Federation
Research Site
Moscow , 12528, Russian Federation
Research Site
Moscow , 14342, Russian Federation
Research Site
Nizhny Novgorod , 60312, Russian Federation
Research Site
Novosibirsk , 63009, Russian Federation
Research Site
Obninsk , 24903, Russian Federation
Research Site
Perm , 61499, Russian Federation
Research Site
Saint Petersburg , 19103, Russian Federation
Research Site
Saint Petersburg , 19702, Russian Federation
Research Site
Saint Petersburg , 19775, Russian Federation
Research Site
Singapore , 16961, Singapore
Research Site
Singapore , 30843, Singapore
Research Site
Barcelona , , Spain
Research Site
Málaga , 29010, Spain
Research Site
Valencia , 46010, Spain
Research Site
Vigo , 36312, Spain
Research Site
Zaragoza , 50009, Spain
Research Site
Taichung , 40201, Taiwan
Research Site
Taichung , 40705, Taiwan
Research Site
Tainan , 70403, Taiwan
Research Site
Taipei City , 114, Taiwan
Research Site
Taipei , 100, Taiwan
Research Site
Taipei , 11217, Taiwan
Research Site
Taipei , 235, Taiwan
Research Site
Taoyuan , 333, Taiwan
Research Site
Bangkok , 10300, Thailand
Research Site
Bangkok , 10330, Thailand
Research Site
Bangkok , 10700, Thailand
Research Site
Hat Yai , 90110, Thailand
Research Site
Khon Kaen , 40002, Thailand
Research Site
Muang , 50200, Thailand
Research Site
Ankara , 06010, Turkey
Research Site
Bursa , 16059, Turkey
Research Site
Istanbul , , Turkey
Research Site
Izmir , 35040, Turkey
Research Site
Kadıkoy/Istanbul , 34722, Turkey
Research Site
Birmingham , B9 5S, United Kingdom
Research Site
Blackpool , FY3 8, United Kingdom
Research Site
Headington , OX3 7, United Kingdom
Research Site
London , SE1 9, United Kingdom
Research Site
London , SW10 , United Kingdom
Research Site
London , SW3 6, United Kingdom
Research Site
Nottingham , NG5 1, United Kingdom
Research Site
Wythenshawe , M23 9, United Kingdom
Research Site
Hanoi , 10000, Vietnam
Research Site
Ho Chi Minh city , 70000, Vietnam
Research Site
Ho Chi Minh , 70000, Vietnam

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

380

Study ID:

NCT05120349

Recruitment Status:

Recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.